# Supriya Lifescience share price today (Supriya Lifescience Ltd, NSE: SUPRIYA)

> Supriya Lifescience share price today: ₹859.90 at the NSE close on 4 November 2026, up 9.0% in a year. Supriya Lifescience (NSE: SUPRIYA) is worth ₹6,923 crore, trades at a P/E of 34.8 and has closed between ₹576.90 and ₹1,009.30 over the past 52 weeks. > Supriya Lifescience Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SUPRIYA · Pharma - API & CRAMS · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/supriya-lifescience-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: ₹859.90 (+9.0% in a year)
- P/E: 34.8× (higher than 87% of the last 4.8 years)
- Revenue (Jun 2026): ₹190 Cr (+31.0% on a year ago)
- Profit (Jun 2026): ₹24.0 Cr (−31.4% on a year ago)
- Operating margin: 25.0% (−11.0 points on a year ago)
- ROCE: 25%, FY26
- ROIC: 17.0%, against a 12.0% cost of capital: +5.0 points

Biggest thing to watch: the P/E is higher than 87% of its own history, so the multiple has already done part of the work. ## What is the Supriya Lifescience share price today? Supriya Lifescience Ltd's share price was ₹859.90 at the close on 4 November 2026. It has been rising for 22 weeks. That is 5.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹577 and ₹1,009, and at that close it sat 65% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row. Over the last 4.8 years the share price moved +78% while the NIFTY 500 moved +42%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Supriya Lifescience this quarter? Three changes stood out: profit fell in the June 2026 quarter, lowest operating margin in 11 quarters and revenue up on a year earlier for 4 quarters in a row. 1. Profit fell in the June 2026 quarter Profit was ₹24 crore, -31.4% on a year earlier (₹35 crore), after 3 quarters of growth. Why: Profit fell because power and solvent costs rose. Next results: check whether profit recovers as the operating margin moves back toward the yearly range. From the earnings call on 14 Aug 2026. 2. Lowest operating margin in 11 quarters Operating margin was 25% in the June 2026 quarter, against 36% a year earlier. Why: The operating margin fell because a water shortage at Lote for 15 to 20 days pushed back sales. Next results: check whether the operating margin recovers toward the yearly range. From the earnings call on 14 Aug 2026. 3. Revenue up on a year earlier for 4 quarters in a row In the June 2026 quarter revenue was ₹190 crore, +31% on a year earlier. Why: Revenue rose because demand stayed strong, even though a water shortage at Lote pushed some sales to a later date. Next results: check whether the sales pushed back from the June quarter show up, since management did not commit to a Q2 recovery. From the earnings call on 14 Aug 2026. ## What are Supriya Lifescience's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Supriya Lifescience reported revenue of ₹190 crore, up 31.0% from ₹145 crore a year earlier, and a profit of ₹24.0 crore, down 31.4% from ₹35.0 crore. ### Supriya Lifescience results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹190 crore | ₹145 crore | +31.0% |
| Profit | ₹24.0 crore | ₹35.0 crore | −31.4% |
| Earnings per share | ₹2.99 | ₹4.32 | −30.8% |
| Operating margin | 25.0% | 36.0% | −11.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Supriya Lifescience's management discussed these results on a call held on 14 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Supriya Lifescience share price history? Supriya Lifescience closed at ₹859.90 on 4 November 2026, up 9.0% from ₹788.85 a year earlier (7 November 2025) and up 248.5% over three years. Its highest weekly close since December 2021 was ₹1,009.30 on 1 July 2026. ### Supriya Lifescience share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹847.30 | +1.5% |
| 1 month ago · 1 Oct 2026 | ₹931.00 | −7.6% |
| 6 months ago · 8 May 2026 | ₹706.70 | +21.7% |
| 1 year ago · 7 Nov 2025 | ₹788.85 | +9.0% |
| 3 years ago · 3 Nov 2023 | ₹246.75 | +248.5% |
| Earliest weekly close in our records · 31 Dec 2021 | ₹483.70 | +77.8% |
| Highest weekly close since December 2021, also the 52-week high · 1 Jul 2026 | ₹1,009.30 | −14.8% |
| Lowest weekly close since December 2021 · 24 Mar 2023 | ₹182.30 | +371.7% |
| 52-week low (weekly close) · 13 Mar 2026 | ₹576.90 | +49.1% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (261 weekly closes from 31 December 2021 to 4 November 2026.)

## What is the latest news on Supriya Lifescience? 4 Nov 2026: Supriya Lifescience closed at ₹859.90, up 1.5% on the week and down 7.6% on the month. 4 Sep 2026: ex-date for a dividend of ₹1 a share. ### Earlier

- 14 Aug 2026: Supriya Lifescience held its results call for April to June 2026. Management guided: FY27 revenue milestone of ₹1,000 crore remains on track. - Results for April to June 2026: Revenue up 31.0% and profit down 31.4% on a year earlier. ## What dividend does Supriya Lifescience pay? Supriya Lifescience paid ₹1 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.12% at the ₹859.90 close on 4 November 2026. The last was a dividend of ₹1 a share, ex-date 4 September 2026. ### Supriya Lifescience dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 4 Sep 2026 | ₹1 | Dividend | same day |
| 4 Sep 2025 | ₹1 | Dividend | 5 Sep 2025 |
| 20 Sep 2024 | ₹0.80 | Dividend | n/a |
| 15 Sep 2023 | ₹0.60 | Dividend | n/a |
| 1 Sep 2022 | ₹0.60 | Dividend | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Supriya Lifescience Ltd paid out 4% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 10 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## What did Supriya Lifescience management say on the latest results call? On the call for April to June 2026, held on 14 August 2026, Supriya Lifescience's management guided: FY27 revenue milestone of ₹1,000 crore remains on track. > “These challenges were largely external and transient in nature. Excluding these one-off impacts, margins would have remained within our guided range.”
> Shivani Wagh, Joint Managing Director, on the call for April to June 2026

### What management guided

- FY27 operating margin 33-35%; one Q&A response used a different lower bound before later answers retained this range. - Approximately 20% growth trajectory over the following 3-4 years; stronger H2FY27 ramp and non-linear quarterly delivery. - Contrast media launch planned H2FY27; Ambernath EU audit scheduled for second half November and anesthetic API CEP expected October-November. - Patalganga Phase 1 around ₹200 crore, API and utilities first; MIDC requires approximately 40% completion within 2.5 years; FY27 depreciation ₹35-40 crore, including ₹14-15 crore from Ambernath. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/44091/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 14 August 2026.)

## What is the future of Supriya Lifescience? What is changing in the business? What is changing at Supriya Lifescience, from the latest results and calls: cdmo and dsm partnership ramp, capacity expansion (patalganga & ambernath) and backward integration & pricing power. - CDMO and DSM Partnership Ramp. DSM contract scaling to a higher peak, with new liquid anesthetic CMO contracts in advanced stages. ⚠ estimate
- Capacity Expansion (Patalganga & Ambernath). Phase-one capital spending at Patalganga and Ambernath semi-regulated commercialization unlocks new volume growth. ⚠ estimate
- Backward Integration & Pricing Power. Achieved high backward integration, protecting margins despite solvent price spikes. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the latest results, written 27 June 2026.)

## What could change the Supriya Lifescience story? What are the risks? A delay in the Ambernath EU audit beyond the guided timeframe, or operating margin falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. ### Each change stops working if

- CDMO and DSM Partnership Ramp: The liquid anesthetic CMO term sheet falls through or is delayed beyond FY27. ### The main risks

- Regulatory Audit Delays (Ambernath): Ambernath EU EMA audit expected soon; any delay stalls the margin-accretive regulated market ramp. ✓ fact
- Product Launch Delays (Contrast Media): Contrast media launch delayed for process optimization. ✓ fact

(Our read after the latest results, written 27 June 2026.)

## What to watch in Supriya Lifescience's next results? When Supriya Lifescience reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Q2 operating margin recovery toward the annual range - check cost normalization, production recovery and customer pass-through. - What to check (from the call)
- Q2 operating margin recovery toward the annual range - check cost normalization, production recovery and customer pass-through. - Ambernath regulated-market readiness - check EU audit completion, customer qualification batches and initial revenue conversion. - Customs consignment resolution - check High Court outcome, CBN regularization and any provision or reversal. - Large anesthetic CDMO term sheet - check signing and disclosed economics after backend qualification. ## Which stock lists is Supriya Lifescience on? Supriya Lifescience is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 6920.403753098076](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Supriya Lifescience profitable? Supriya Lifescience Ltd earned ₹24.0 Cr of net profit in the Jun 2026 quarter, −31.4% on the same quarter a year earlier. Full-year FY26 profit was ₹209 Cr. Over 9 years profit has grown 48.4% a year on average. That is 12.6% of the quarter's revenue. The same quarter a year earlier earned ₹35.0 Cr. For the full year, FY26 profit was ₹209 Cr (+11.2% on the year before). Why profit moved: revenue changed +31.0% on a year earlier and the margin moved −11.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +7.9% and revenue +28.2%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Supriya Lifescience make, and is it growing? Supriya Lifescience Ltd reported ₹190 Cr of revenue in the Jun 2026 quarter, +31.0% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 9 years it has grown 18.2% a year on average. The last full year, FY26, came in at ₹828 Cr. Why this happened. The pivot to CDMO is materializing. With DSM volumes stabilized and liquid anesthetic CMO contracts in advanced term-sheet negotiations, this diversifies revenue away from pure API sales. The last four reported quarters add to ₹873 Cr. FY26 revenue was ₹828 Cr, +19.0% on the year before. Recent pace: the last four quarters grew +28.2% on average, against 18.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +28.2%, against +20.7% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +11.2%, against +20.7% a year (rolling over). ## How much of every ₹100 of sales does Supriya Lifescience keep? Supriya Lifescience Ltd's operating margin was 25.0% in the Jun 2026 quarter, 11.0 percentage points lower than the same quarter a year ago. Across 10 years it has been between 9.0% and 44.0%. The latest quarter is within that range. Why this happened. Capacity constraints are being addressed. Patalganga groundbreaking and the F-block Lote extension provide the runway for the revenue goal and beyond. Why the margin moved: operating margin changed −10.6 percentage points on the year while gross margin changed −7.8 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Supriya Lifescience's profit turning into cash? Over the last 3 years, 90% of Supriya Lifescience Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹186 Cr of operating cash against ₹209 Cr of profit. After ₹152 Cr of spending on assets, ₹34.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 90% of profit came in as cash: the cash cycle got 37 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 7.2× depreciation over three years. The next section checks what that spending is building. ## Where does Supriya Lifescience's cash go? Supriya Lifescience Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 167 days in FY26, up from 130 days in FY21. It spent ₹459 Cr on assets over the last 3 years. Customers take 97 days to pay, and stock sits for 229 days on average. At FY26 sales of ₹828 Cr, each day of that cycle ties up about ₹2.3 Cr, so roughly ₹379 Cr is tied up in the business at any time. FY26: customers took 97 days to pay and stock sat for 229 days, about 7.5 months of sales sitting as stock, for a full cycle of 167 days, longer than FY21's 130. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 229 days. Customers pay about 97 days after that. Suppliers are paid at 159 days. Together that makes the 167-day cycle. Spending on assets: ₹459 Cr over the last 3 years, against ₹64.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹36.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Supriya Lifescience's P/E ratio, and how does it compare with its own history? Supriya Lifescience Ltd's P/E is 34.8×, near the high end of its own history: higher than 87% of past readings. Its usual P/E (the middle reading) is 27.9×, over 4.8 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +11.3% while the price moved +9.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved +51.6% a year; about +28.8% a year came from earnings growth and about +22.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Supriya Lifescience business getting better or worse? Supriya Lifescience Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 23.7%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## What is the Supriya Lifescience story, and has it been checked? Supriya Lifescience Ltd's story is not scored yet against the checks our research set on 27 June 2026. Where it sits in its own cycle: AT PEAK. Still open: A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. Our read, 27 June 2026. From the numbers. From the price. Price stage 2, week 22, above its 200-day line, relative strength rising. From the research. Where they disagree. What is proven. What is not proven yet. A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. What would change our mind. A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. The test written in advance. A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. Measured by: the thesis as written as stated by the next result. The test written in advance. Regulatory Audit Delays (Ambernath). Measured by: Regulatory Audit Delays (Ambernath) EU audit scheduling confirmation in Q2/Q3 FY27 calls by the next result. The test written in advance. What the company does. FY26 revenue hit record highs with OPM steady, proving their ability to pass through raw material cost spikes. Regulatory hurdles cleared with a VAI for the Lote facility, and new capex is planned for Patalganga to support the revenue goal. What the surface reading misses. Lever 6 · Order-book wins: building. DSM contract scaling to a higher peak, with new liquid anesthetic CMO contracts in advanced stages. What proves it keeps working: CDMO and DSM Partnership Ramp. It stops working if The liquid anesthetic CMO term sheet falls through or is delayed beyond FY27. Lever 1 · Operating leverage: building. Phase-one capex at Patalganga and Ambernath semi-regulated commercialization unlocks new volume growth. What proves it keeps working: Capacity Expansion (Patalganga & Ambernath). It stops working if A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. Lever 2 · Value-added mix: building. Achieved high backward integration, protecting margins despite solvent price spikes. What proves it keeps working: Backward Integration & Pricing Power. It stops working if A delay in the Ambernath EU audit beyond the guided timeframe, or OPM falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. Sources: our stock research file (27 June 2026) · quarterly results through Jun 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Supriya Lifescience management deliver what it promised? What Supriya Lifescience Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. ATS Volume Timing Reframed · 14 August 2026. In February 2026, management stated that it expected to fully achieve 250 to 300 tons in FY27. In August 2026, management said the 250-ton figure represented a two-year outcome and explicitly stated that it had not guided to that volume for FY27, materially changing the near-term volume assumption without reconciling the prior statement. Contrast Media Timeline Deferred · 28 May 2026. In the November 2025 and February 2026 calls, management indicated the contrast media product would be launched in the fourth quarter of FY26. However, in the May 2026 call, they pushed this launch out to the second half of FY27 to perform further R&D on process optimization. Cardiovascular Intermediate Volume Goal Contradicted · 28 May 2026. In the February 2026 call, management explicitly confirmed that the entire 250 to 300 metric tons of cardiovascular intermediate demand would be fully realized in FY27. However, in the May 2026 call, they changed this position, stating that these volumes will not come fully in FY27 and will instead manifest over the next two to three years. Protein Project Revenue Forecast Cut · 28 May 2026. In the November 2025 call, management expected the Whey Protein contract to scale quickly and generate the majority of its potential revenue in FY27. However, in the May 2026 call, they stated that they do not see any large revenues coming from this project in FY27 as formulation development continues. Every quote above is taken word for word from the company’s own earnings calls. ## How much does Supriya Lifescience earn on its capital? Supriya Lifescience Ltd earned a ROCE of 25% in FY26. That is up from a low of 14% in FY18. Its return on capital used (ROIC) is 5.0 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 25.2% net margin and 0.61× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 25.2% net margin × 0.61× asset turnover × 1.13× leverage (assets divided by equity) ≈ 17.4% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 17.0% − 12.0% = +5.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 17.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 19.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Supriya Lifescience have too much debt? Supriya Lifescience Ltd has total debt of ₹5.0 Cr against shareholder equity of ₹1,198 Cr as of Jun 2026, so its debt is 0.00× its equity, which is very little. Year by year, that ratio went from 0.04 in FY22 to 0.00 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Supriya Lifescience shareholding pattern? No group of Supriya Lifescience Ltd's owners changed its stake by a full percentage point over the last two years. Promoters moved +0.0 points over the same period, to 68.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +0.4 points over 8 quarters, to 6.5%; Promoters: +0.0 points over 8 quarters, to 68.3%; Domestic institutions: +0.0 points over 8 quarters, to 5.5%. ## How far is Supriya Lifescience from balance-sheet trouble? For Supriya Lifescience Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Supriya Lifescience rank in its industry? 43.7 out of 100, rank 17 of 24 in Pharma - API & CRAMS, with 96% of the evidence available. Supriya Lifescience Ltd scores 43.7 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 17. A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. The four parts add up to the total exactly: 15.6 + 16.9 + 6.2 + 5 = 43.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Supriya Lifescience compared with? Supriya Lifescience ranks 17 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 43.7 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. [Piramal Pharma Ltd](https://www.sectoralpha.in/stocks/piramal-pharma-ltd) PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative
17. Supriya Lifescience Ltd this page SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.6/35 · Revenue 28.2% · Profit 11.2% · Operating margin change -11 points · 88% evidence Capital efficiency 16.9/25 · ROCE 25.2% · Operating margin 25% · 100% evidence Valuation 6.2/20 · P/E 34.3× · PEG 3.11 · 100% evidence Relative strength 5.0/20 · Lead over its industry -13.6% · Lead over NIFTY 500 14% · 1 year 9.1% · 100% evidence · 5 of 12 weeks ahead Exact sum: 15.6 + 16.9 + 6.2 + 5 = 43.7 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Supriya Lifescience in size? Supriya Lifescience is the 17th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Jubilant Pharmova, Concord Biotech and Blue Jet Healthcare. Just below it: Morepen Laboratories, IOL Chemicals & Pharmaceuticals and SMS Pharmaceuticals. ### Pharma - API & CRAMS companies close in size

1. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) ₹14,716 crore
2. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) ₹13,031 crore
3. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) ₹9,550 crore
4. Supriya Lifescience Ltd ₹6,819 crore
5. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) ₹6,211 crore
6. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) ₹5,215 crore
7. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) ₹4,789 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Power Mech Projects Ltd](https://www.sectoralpha.in/stocks/power-mech-projects-ltd) ₹6,839 crore · Project Consultancy/Turnkey
2. [SML Mahindra Ltd](https://www.sectoralpha.in/stocks/sml-mahindra-ltd) ₹6,836 crore · Auto - Bus/LCVs
3. Supriya Lifescience Ltd ₹6,819 crore
4. [Ceigall India Ltd](https://www.sectoralpha.in/stocks/ceigall-india-ltd) ₹6,797 crore · Construction - Civil/Turnkey
5. [Relaxo Footwears Ltd](https://www.sectoralpha.in/stocks/relaxo-footwears-ltd) ₹6,784 crore · Footwear

## What else do people ask about Supriya Lifescience? ### What is Supriya Lifescience's share price today? Supriya Lifescience Ltd's share price is ₹859.90, +9.0% over the past year. The whole company is worth ₹6,923 Cr on the market. In the last 52 weeks it traded between ₹577 to ₹1,009; today it is 65% of the way up from the low, 5.6% above its 200-day average (as of 4 November 2026). ### What were Supriya Lifescience's latest quarterly results? Supriya Lifescience Ltd reported revenue of ₹190 Cr and net profit of ₹24.0 Cr for the Jun 2026 quarter. Revenue rose 31.0% and profit fell 31.4% compared with a year earlier. Earnings per share were ₹2.99. The operating margin was 25.0%, 11.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is Supriya Lifescience's market cap? Supriya Lifescience Ltd's market capitalisation is ₹6,923 Cr at a share price of ₹859.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Supriya Lifescience performing? Supriya Lifescience Ltd's share price has been rising for 22 weeks. In its latest quarter, revenue rose 31.0% and profit fell 31.4% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 1 week running (as of 4 November 2026). ### Will Supriya Lifescience's share price go up? This page does not forecast Supriya Lifescience Ltd's share price. What it shows instead: the share price is ₹859.90, and it has been rising for 22 weeks. Its P/E of 34.8× is higher than 87% of its own last 5 years (as of 4 November 2026). ### Does Supriya Lifescience have too much debt? No, Supriya Lifescience Ltd has little debt: its debt is 0.00× its equity, and its operating profit is 98 times its interest bill. FY26 borrowings were ₹5.0 Cr against equity of ₹1,198 Cr. So the returns on this page come from the business, not borrowed money (as of 4 November 2026). ### Where is Supriya Lifescience in its business cycle? Supriya Lifescience Ltd's FY26 operating margin was 36.0%, against a 10-year range of 9.0% to 44.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 25.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Supriya Lifescience story? Biggest thing to watch: the P/E is higher than 87% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Supriya Lifescience a stock worth studying right now? What the numbers show: Supriya Lifescience Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a Supriya Lifescience share price forecast for 2026? What management itself guided: FY27 revenue milestone of ₹1,000 crore remains on track. What is changing at Supriya Lifescience, from the latest results and calls: cdmo and dsm partnership ramp, capacity expansion (patalganga & ambernath) and backward integration & pricing power. What would change the story: A delay in the Ambernath EU audit beyond the guided timeframe, or operating margin falling below historical ranges due to an inability to pass through solvent costs, would break the execution premium thesis. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.